Literature DB >> 14654560

Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.

Martha C Kutko1, Richard D Glick, Lisa M Butler, Dennis C Coffey, Richard A Rifkind, Paul A Marks, Victoria M Richon, Michael P LaQuaglia.   

Abstract

PURPOSE: A group of histone deacetylase inhibitors has been shown to be effective in suppressing the growth of a variety of transformed cell lines in vitro and in vivo. The effects of two of these agents, suberoylanilide hydroxamic acid (SAHA) and suberoyl-3-aminopyridineamide hydroxamic acid (pyroxamide), were investigated for their growth-suppressive effects on rhabdomyosarcoma (RMS) cells. EXPERIMENTAL DESIGN AND
RESULTS: Dose-response experiments of two RMS cell lines, RD (embryonal) and RH30B (alveolar), were performed with SAHA (0.25-3.0 micro M) and pyroxamide (1.25-20.0 micro M). Both agents caused a dose-dependent decrease in viable cell number and an increase in percentage of dead cells over time. Exposure of the RMS cells to SAHA and pyroxamide resulted in an accumulation of acetylated histones with increasing doses by Western blot analysis. Additionally, there was an induction of p21/WAF1 at 15 and 24 h when the cells were cultured with SAHA (2.0 micro M) or pyroxamide (20.0 micro M), concentrations that were tested because they successfully induced inhibition of cell growth and initiated cell death in both RMS cell lines. An increase in nuclei with hypodiploid or sub-G(1) fraction was found by flow cytometry with increasing doses of both SAHA (0.25-3.0 micro M) and pyroxamide (1.25-20.0 micro M) over time. This finding is consistent with DNA fragmentation and cell death by apoptosis.
CONCLUSIONS: SAHA and pyroxamide induce growth suppression and cell death in human RMS in vitro. Accumulation of acetylated histones and induction of p21/WAF1 expression are observed in cells exposed to either agent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14654560

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

Review 1.  Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications.

Authors:  Roberta Ciarapica; Lucio Miele; Antonio Giordano; Franco Locatelli; Rossella Rota
Journal:  BMC Med       Date:  2011-05-25       Impact factor: 8.775

Review 2.  Therapeutic applications of histone deacetylase inhibitors in sarcoma.

Authors:  Fan Tang; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2017-07-06       Impact factor: 12.111

3.  PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.

Authors:  Berkley E Gryder; Marielle E Yohe; Hsien-Chao Chou; Xiaohu Zhang; Joana Marques; Marco Wachtel; Beat Schaefer; Nirmalya Sen; Young Song; Alberto Gualtieri; Silvia Pomella; Rossella Rota; Abigail Cleveland; Xinyu Wen; Sivasish Sindiri; Jun S Wei; Frederic G Barr; Sudipto Das; Thorkell Andresson; Rajarshi Guha; Madhu Lal-Nag; Marc Ferrer; Jack F Shern; Keji Zhao; Craig J Thomas; Javed Khan
Journal:  Cancer Discov       Date:  2017-04-26       Impact factor: 39.397

4.  Anaplasma phagocytophilum increases the levels of histone modifying enzymes to inhibit cell apoptosis and facilitate pathogen infection in the tick vector Ixodes scapularis.

Authors:  Alejandro Cabezas-Cruz; Pilar Alberdi; Nieves Ayllón; James J Valdés; Raymond Pierce; Margarita Villar; José de la Fuente
Journal:  Epigenetics       Date:  2016-03-28       Impact factor: 4.528

5.  Role of epigenetic modulation for the treatment of sarcoma.

Authors:  Gregory M Cote; Edwin Choy
Journal:  Curr Treat Options Oncol       Date:  2013-09

6.  Chromatin structure predicts epigenetic therapy responsiveness in sarcoma.

Authors:  Joslyn Mills; Todd Hricik; Sara Siddiqi; Igor Matushansky
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

7.  Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.

Authors:  Chana L Glasser; Alice Lee; Don Eslin; Lianna Marks; Shakeel Modak; Julia L Glade Bender
Journal:  J Pediatr Hematol Oncol       Date:  2017-10       Impact factor: 1.289

8.  Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.

Authors:  George R Blumenschein; Merrill S Kies; Vassiliki A Papadimitrakopoulou; Charles Lu; Ashok J Kumar; Justin L Ricker; Judy H Chiao; Cong Chen; Stanley R Frankel
Journal:  Invest New Drugs       Date:  2007-10-25       Impact factor: 3.850

9.  TBX2 blocks myogenesis and promotes proliferation in rhabdomyosarcoma cells.

Authors:  Bo Zhu; Meiling Zhang; Stephanie D Byrum; Alan J Tackett; Judith K Davie
Journal:  Int J Cancer       Date:  2014-01-27       Impact factor: 7.396

Review 10.  Pediatric Rhabdomyosarcoma.

Authors:  Jack F Shern; Marielle E Yohe; Javed Khan
Journal:  Crit Rev Oncog       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.